Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Andreas Halvorsen’s Viking Global initiated in $ONTY

Andreas Halvorsen’s Viking Global initiated a brand new position in Oncothyreon Inc. (ONTY). On Sep 26th, Viking Global revealed in a 13G filing that the firm had purchased 2.96 million shares of ONTY, corresponding to a 7.1% passive stake. Viking Global previously didn’t own any shares in ONTY, and it passed the 5% threshold on September 14th. Since then ONTY was wavering in narrow channel between $6 and $7.5, Andreas Halvorsen probably made most of his purchases at around $6.

Andreas Halvorsen

Among the more than 300 hedge funds we tracked in the second quarter, seven had ONTY in their portfolios. Samuel Isaly’s Orbimed Advisors owned significantly more shares than the other hedge funds, with nearly 1.4 million shares, corresponding to 3.6% of ONTY’s outstanding shares. If no large transaction was made after June, Viking Global is most probably ONTY’s No.1 hedge fund stakeholder.

Viking Global was launched by Norwegian Halvorsen at the end of 1999 with former Tiger employees David Ott and Brian Olson. The firm is a long/short global equity fund with a bottom-up stock picking approach. It returned an astonishing 89% after fees in its first full year. The firm had a 13F portfolio of nearly $12 billion in the second quarter, with most of the investments focused on Services, Financial, Healthcare, and Basic Materials. (see more)

Oncothyreon Inc. is a clinical-stage biopharmaceutical company providing therapeutic products for the treatment of cancer. The company mainly operates in United States, Canada, and Europe.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!